Articles tagged with Clinical Trials
The African-led PrEPVacc trial has completed participant enrolment at all four sites in East and Southern Africa. The trial is testing two different ways to prevent HIV, including HIV vaccine regimens and a new form of oral pre-exposure prophylaxis (PrEP).
Researchers have made a breakthrough in treating melanoma by adding an mRNA vaccine tailored to individual tumour genetics to common immunotherapy, significantly improving survival and disease recurrence rates. After two years, cancer-free survival increased to 78.6%, and the risk of death or cancer returning was reduced by 44%.
The BCG vaccine, primarily developed to prevent tuberculosis, was found ineffective against COVID-19 in a large international trial involving nearly 4,000 healthcare workers. Researchers discovered that vaccination increased the risk of symptomatic disease during the first six months following enrolment.
A recent commentary highlights a potential hidden source of bias in electronic health records, which can impact clinical trials. Embedded pragmatic clinical trials rely heavily on EHRs for data collection, excluding people from underrepresented groups due to lack of access or inaccurate data collection.
A recent study published in The Journal of Orthopaedics found that patients who underwent partial meniscectomy using a needle arthroscopic technique experienced significantly less pain and improved patient-reported outcomes at two weeks after surgery. However, differences were not sustained at six weeks.
A randomized clinical trial found that peer health coaching improved mental health-related quality of life in veterans with cardiovascular disease risks. The study suggests a peer-support model integrated into primary care can lead to well-being improvements beyond blood pressure control.
Researchers analyzed data from 120 clinical trials and found no evidence that treatment efficacies differ depending on the number of comorbidities. The study suggests that modest levels of comorbidities do not affect treatment outcomes, providing valuable insights for clinicians to make informed recommendations.
A supervised hospital walking program has been shown to reduce nursing facility admissions for older adults by lowering the proportion of patients discharged to skilled nursing facilities from 13% to 8%. However, low participation rates and limited impact on length of stay or inpatient falls were noted.
Researchers at Sanford Burnham Prebys have discovered a new treatment for autoimmune diseases using LY3361237, an antibody that activates BTLA to inhibit the immune system. The study provides insight into the molecular biology of the immune system and could lead to the development of more effective therapies.
Erdafitinib achieves tumor-agnostic benefits across 16 cancer types, including urothelial, lung, and other cancers. The trial demonstrated a disease control rate of 73.7% and clinical benefit rate of 45.6%, with notable improvements in pancreatic and cholangiocarcinoma patients.
The Phase 3 S1826 trial demonstrates one-year progression-free survival in 94% of patients with Stage 3 or 4 classic Hodgkin lymphoma treated with nivolumab and chemotherapy. The therapy was well-tolerated, with few serious immune-related side effects.
A phase 3 clinical trial by Dana-Farber Cancer Institute has shown vorasidenib significantly prolongs progression-free survival and delays radiation and chemotherapy for patients with Grade 2 IDH-mutant glioma. Treatment with vorasidenib can delay cognitive dysfunction in patients and preserve their quality of life.
A new targeted therapy drug vorasidenib has been shown to extend treatment time without worsening glioma in people with IDH1 and IDH2 mutations. The study suggests a possible new treatment option for slow-growing but deadly brain tumors, delaying chemotherapy and radiation.
Analysis of rare cancer patients treated with checkpoint inhibitors reveals a linear correlation between tumor shrinkage and patient survival, contradicting earlier threshold-based models. The study suggests that using partial- or complete-response rates may miss signals of longer survival.
A study found that adding ribociclib to hormone therapy significantly improves invasive disease-free survival rates in patients with stage 2 or 3 HR positive/HER2 negative breast cancer. The combination therapy reduced the risk of cancer recurrence by 25%, with a three-year invasive disease-free survival rate of 90.4%.
A Phase II trial led by MD Anderson Cancer Center showed that zanidatamab achieved a 41% confirmed objective response rate and durable responses in HER2-positive biliary tract cancer. This represents the largest study of a HER2-targeted drug in BTC, providing evidence for its potential as a new treatment option.
A phase II trial showed that patients with extensive stage SCLC expressing the Schlafen-11 gene had significantly longer progression-free survival when treated with atezolizumab and talazoparib. The study demonstrates improved outcomes for patients with SLFN11-positive SCLC, paving the way for personalized therapy approaches.
A phase 2 trial found that immune checkpoint inhibitor pembrolizumab had a durable antitumor effect in 24 of 57 patients with metastatic brain cancer. The study achieved its primary endpoint, with median overall survival of 8 months and seven patients surviving longer than two years.
A randomized clinical trial suggests that low-dose atropine may provide a treatment option for childhood myopia progression. The study observed a significant reduction in myopia progression over 3 years.
In a multicenter trial, pirtobrutinib demonstrated reversible and effective inhibition of defective B-cells in patients with poor survival prognosis. Over half of patients responded to the drug, with a median duration of response of 21.6 months.
A new clinical trial found that low-dose atropine eye drops are effective in slowing the progression of nearsightedness in children. The treatment showed significant improvements in limiting eyeglass prescription changes and inhibiting elongation of the eye, with a daily drop in each eye being enough to make a difference.
The SISAQOL-IMI Consortium establishes an international consensus on patient-reported outcomes in cancer trials, aiming to improve the use of PROs. The new standards will enhance patient involvement and ensure the relevance of recommendations to the patient community.
Decentralized trials aim to improve access to clinical research, but disparities in technology access and potential barriers to trust remain unknown. Rigorous randomized controlled trials are needed to evaluate the impact of decentralized trials on trial enrollment and pipeline aspects.
Researchers found that a reduction in body weight of 1% led to participants' brain age being almost 9 months younger than expected. This attenuation of brain aging was associated with changes in liver fat and enzymes, which can negatively affect brain health in Alzheimer's disease.
Researchers found that ropinirole is safe and effective in slowing ALS progression, with patients showing improved physical activity and muscle strength after treatment. The study suggests that the method of growing motor neurons from patient-derived stem cells could be used to predict a patient's response to the drug.
A large study tracked CIPN in over 1,100 breast cancer patients treated with taxanes, showing persistent sensory and motor symptoms with more severe symptoms with paclitaxel than docetaxel. The study defines a risk prediction model to help doctors individualize patient care.
A recent study has demonstrated the safety and effectiveness of a liver dialysis device in treating acute-on-chronic liver failure (ACLF). The device, DIALIVE, was associated with significant improvements in symptoms and organ function compared to standard care.
The SWOG Cancer Research Network will present 30 abstracts at the ASCO 2023 annual meeting, highlighting primary results from trials S1011, S1826, S1714, and S1929. Additionally, analysis from the S1609 DART trial will be shared publicly during the meeting.
Researchers presented findings on pembrolizumab for brain metastases, virtual mind-body interventions for post-treatment survival, and dynamic HER2-low status in triple negative breast cancer. The studies aim to improve treatments and outcomes for patients with cancer.
A clinical trial using DIALIVE, a novel liver dialysis device, demonstrated significant improvements in all main underlying pathophysiological mechanisms of acute-on-chronic liver failure. Treatment resulted in accelerated resolution of ACLF and sustained improvement in biomarkers.
Two Kessler Foundation scientists will conduct studies on upper extremity exercise after stroke and restoration of cardiovascular function in spinal cord injury populations. Dr. Shenoy Handiru's study combines transcranial electrical stimulation and wearable sensor-based exergaming to improve hand dexterity, while Dr. Einat Engel-Haber...
A phase 3 trial found that extending lymphadenectomy beyond the standard procedure does not reduce disease recurrence or improve survival in patients with locally advanced bladder cancer. Instead, it increases the risk of adverse events and post-surgical death.
Dana-Farber researchers present promising results for patients with rectal, brain, and kidney cancers in phase 3 trials. The PROSPECT trial shows neoadjuvant chemoradiation versus FOLFOX chemotherapy offers improved survival benefits for locally advanced rectal cancer patients. Additionally, the INDIGO trial demonstrates vorasidenib's ...
A Canadian study found that eliminating out-of-pocket medication expenses for patients with cost-related nonadherence results in lower healthcare spending over three years. The analysis suggests that reducing medication costs could lead to significant savings in the overall healthcare system.
Researchers at UTHealth Houston are investigating the role of fibrin and fibrinogen in traumatic brain injury and hemorrhagic shock. The four-year grant will fund Phase II of a stem cell clinical trial evaluating whether mesenchymal stem cells reduce chronic neuroinflammatory response to traumatic brain injury.
The Alzheimer's disease development pipeline has seen an increase in promising therapies and pharma investment, driving momentum in clinical trials. The pipeline currently has 187 clinical trials, with recent FDA approvals for two disease-modifying therapies, and more on the way.
A clinical trial found that a telephone-based weight loss program can help breast cancer patients with overweight or obesity lower their weight by a significant degree. Women who received the program lost an average of 4.8% of their baseline body weight, compared to a 0.9% increase in the control group.
Penn Medicine researchers will present results from clinical trials for recurrent glioblastoma and metastatic breast cancer. Experts will also present studies on serious illness conversations, Medicaid expansion impact, and infertility among female oncologists.
The study, published in Science Translational Medicine, shows robust T-cell responses in volunteers participating in a phase 1 clinical trial of a self-assembling nanoparticle HIV vaccine. The antigen used stimulates VRC01-class B cells, an immune response considered promising for boosting in further studies.
A new study published in the European Heart Journal found that plant-based diets can play a significant role in reducing blocked arteries and lowering the risk of heart and blood vessel diseases. The analysis of 30 randomised trials with over 2,300 participants showed a 14% reduction in artery-clogging lipoproteins.
A clinical trial of 403 patients found that ketamine treatment was non-inferior to ECT for treating non-psychotic treatment-resistant depression. Ketamine showed fewer side effects than ECT, with improved depressive symptoms and quality of life.
A study led by Brown University researchers found that qigong practice significantly improved cancer-related fatigue in participants. The program was as effective as a more standard exercise program in reducing fatigue levels.
A new vaccine against meningococcal disease has shown safety and efficacy in a phase 3 trial, generating higher immune responses than existing vaccines across five strains. The vaccine, NmCV-5, also induces a strong response to the emerging meningococcal X strain, providing potential protection against epidemics.
Researchers found that focusing on satiety and satiation through the consumption of fruits and vegetables can lead to better weight loss outcomes. Both diet programs increased levels of satiation and satiety among participants, as well as promoting better quality of life and emotional well-being.
A new international clinical trial is evaluating new antibiotic combinations for newborn babies with sepsis, which affects up to 3 million babies globally. The NeoSep1 trial will assess the safety and efficacy of three new antibiotic treatments against existing standard regimens.
A clinical trial combining TVB-2640 and bevacizumab showed a six-month progression-free survival improvement in patients with recurrent high-grade glioblastoma, warranting further study. The treatment's side effects were mild, but the overall survival of participants was not statistically significant compared to historic controls.
A new treatment has been developed to help people stop needing opioid painkillers for chronic pain, with promising results in a clinical trial. The intervention programme combines one-to-one and group support to guide individuals in coming off opioids, teaching them alternative techniques to manage their pain.
Researchers from the UCLA Jonsson Comprehensive Cancer Center are presenting findings on combination therapies for breast cancer and a potential new treatment for patients with recurrent glioma. A phase 3 study evaluating vorasidenib versus placebo in patients with residual or recurrent grade 2 glioma with an IDH1/2 mutation is also be...
An international consortium led by Amsterdam UMC has developed an improved version of the wireless pacemaker, enabling placement in both the atrium and ventricle of the heart. This innovation expands treatment options for patients with slow heart rhythms, improving contraction and reducing the need for multiple mini pacemakers.
Researchers have developed a pharmacological treatment that improves cardiac function in patients with stiff-heart syndrome, a condition caused by amyloid protein deposition. The new drug reduces amyloid protein deposits and shows promise in reversing established disease symptoms.
The TWILIGHT trial found ticagrelor monotherapy after PCI to have a similar risk of repeat revascularization and MACCE compared to dual antiplatelet therapy. Ticagrelor monotherapy was also associated with lower NACE and clinically-driven revascularization risk.
A study found that expert mammogram radiologists exhibit visual hindsight bias, leading to improved performance on blurry images after prior clear images were viewed. This bias can impact the detection of lesions and has implications for negligence lawsuits and patient outcomes.
A novel low-profile pVAD system demonstrated 100% procedural success and no device-related adverse events in a first-in-human trial. The device supports cardiovascular hemodynamics with minimal hemolysis and low risk of vascular complications, aiming to minimize morbidity and improve patient outcomes
A large-scale clinical trial has found that spironolactone is an effective treatment for persistent acne in women, offering an alternative to antibiotics. The study, funded by the National Institute for Health and Care Research, recruited over 400 women with acne that had persisted for more than six months.
A global clinical trial found that bioresorbable vascular scaffolds (BVS) are nearly as safe and effective as conventional metal stents in treating coronary artery disease. The study, led by a researcher from the Mount Sinai Hospital, showed improved outcomes for patients when properly implanted.
A study by Newcastle University found that tonsillectomy reduces sore throat episodes in adults by 50%, improving quality of life. The procedure is also cost-effective compared to painkillers and antibiotics for eligible patients, aged 16 and over.
A phase IIb trial found brepocitinib superior to placebo in reducing signs and symptoms of psoriatic arthritis after 16 weeks. Response rates were maintained or improved through week 52, with mostly mild or moderate side effects.
The use of drug-coated balloons (DCBs) in coronary angioplasty is gaining importance, particularly for treating in-stent restenosis. Newer devices are being developed, and upcoming trials aim to enhance the evidence base for DCB treatment, especially in patients with de novo disease.
Researchers from China explore the mechanisms of action and clinical data of bispecific antibodies, which have shown promise in increasing cytotoxicity against cancerous cells and enhancing immune response towards tumor clearance. Several bsAbs are being evaluated in phase I-III clinical trials for lung cancer treatment.
Gene therapy is being tested for rare skeletal dysplasia, affecting 1 in 200,000. Patients will receive a one-time infusion of viral vector containing correct gene sequence.